LL-37 vs VIP
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
Also: Vasoactive Intestinal Peptide, Aviptadil
VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for COVID-19 respiratory failure and pulmonary conditions. No VIP product is FDA-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | LL-37 | VIP |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 carries a net positive charge and has a water-loving and fat-loving (amphipathic) structure, which lets it home in on the negatively charged membranes of bacteria and physically punch holes in them. But killing microbes directly is only half the job. It also acts as a signaling molecule: it neutralizes bacterial toxin LPS, calms or tunes the inflammatory response, recruits immune cells to wounds and infection sites, and helps skin re-grow and close over injuries. It is produced by skin, gut, lung, and other epithelial cells, plus immune cells like neutrophils. This dual role, direct antimicrobial plus immune coordinator, is why it is described as a multifunctional host-defense peptide. | VIP works through two G-protein-coupled receptors, VPAC1 and VPAC2, which are spread across immune cells, the gut, blood vessels, and the brain. When VIP binds, the receptor raises intracellular cyclic AMP, and that signal relaxes smooth muscle (so blood vessels and airways dilate) and tamps down inflammatory signaling. On the immune side, that rise in cAMP blunts NF-kB activity and lowers pro-inflammatory cytokines like TNF-alpha, which is the basis for calling VIP an endogenous anti-inflammatory. The same pathway is why researchers looked at it for the runaway lung inflammation seen in severe COVID-19. It is a broadly active hormone, not a targeted single-tissue drug, which is part of why dosing it safely is tricky. |
| Common Dosing | 100-200 mcg daily Once daily | 50-100 mcg intranasal daily 1-2x daily, intranasal |
| Administration | Subcutaneous injection or topical | IV infusion, inhaled, or intranasal |
| Typical Duration | Variable by protocol | Variable by indication |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The basic biology of LL-37 is well established across many peer-reviewed studies. Its broad antimicrobial activity, membrane-disrupting mechanism, and tissue distribution are documented in reviews such as those in the Journal of Leukocyte Biology and PMC-indexed updates on how it limits the spread of local infection. Research has also explored more speculative directions: LL-37 and engineered mimics have shown anticancer activity in laboratory models, and it has been studied as a possible host-defense factor against Helicobacter pylori in the stomach and against pathogens on the surface of the eye. The important honesty point is that almost all of this is mechanistic and preclinical. LL-37 is firmly proven as a natural part of human immunity, but as a deliberately administered therapy it has not cleared large human clinical trials, and its dual nature means it can also drive inflammation in some disease states. So: rock-solid as biology, still experimental as a treatment. | Most of the real human data on VIP comes from aviptadil, the synthetic analog. A randomized controlled trial of intravenous aviptadil in critically ill COVID-19 patients with respiratory failure (about 196 patients, published in Critical Care Medicine in 2022) did not hit its primary endpoint of being alive and free of respiratory failure at 60 days, though there were exploratory signals worth following up. Larger and inhaled formulations were studied through the ACTIV-3b/TESICO program, and the overall picture is mixed rather than a clear win. Beyond the lungs, VIP and its VPAC receptors are studied in rheumatoid arthritis, pulmonary arterial hypertension, and other inflammatory conditions, but that work is largely mechanistic or early-stage. There is no good human evidence supporting the anti-aging, longevity, or general wellness claims VIP is sold for online. Bottom line: a genuinely interesting immune-modulating peptide with real trials, but the trials were in serious illness and did not establish it as an effective therapy. |
Frequently Asked Questions: LL-37 vs VIP
What is the difference between LL-37 and VIP?
LL-37 is a immune peptide that ll-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hcap-18. it is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. this is mainstream, heavily studied human biology, not a fringe research peptide, though ll-37 itself is not an approved drug. VIP is a immune peptide that vip (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. it is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for covid-19 respiratory failure and pulmonary conditions. no vip product is fda-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or VIP?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while VIP is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and VIP be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and VIP together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.